Aprea Therapeutics (APRE) to Release Earnings on Wednesday

Aprea Therapeutics (NASDAQ:APRE) is expected to be releasing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Aprea Therapeutics to post earnings of ($0.23) per share and revenue of $0.0030 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 20, 2026 at 8:00 AM ET.

Aprea Therapeutics (NASDAQ:APRE) last posted its earnings results on Monday, March 16th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%.The company had revenue of $0.00 million for the quarter. On average, analysts expect Aprea Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aprea Therapeutics Stock Down 5.1%

NASDAQ:APRE opened at $0.93 on Tuesday. Aprea Therapeutics has a 52 week low of $0.55 and a 52 week high of $2.22. The company has a market capitalization of $11.52 million, a P/E ratio of -0.47 and a beta of 1.48. The stock’s fifty day moving average is $0.82 and its two-hundred day moving average is $0.93.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.67% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on APRE. HC Wainwright reduced their target price on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Monday, April 20th. Zacks Research upgraded Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Wedbush restated an “outperform” rating and issued a $7.00 target price on shares of Aprea Therapeutics in a research report on Tuesday, March 31st. Finally, Oppenheimer started coverage on Aprea Therapeutics in a research note on Thursday. They issued an “outperform” rating and a $5.00 price objective for the company. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.40.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.